These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34328655)

  • 61. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
    Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G
    BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A model-based multithreshold method for subgroup identification.
    Wang J; Li J; Li Y; Wong WK
    Stat Med; 2019 Jun; 38(14):2605-2631. PubMed ID: 30887552
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A multicenter random forest model for effective prognosis prediction in collaborative clinical research network.
    Li J; Tian Y; Zhu Y; Zhou T; Li J; Ding K; Li J
    Artif Intell Med; 2020 Mar; 103():101814. PubMed ID: 32143809
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Explaining heterogeneity of individual treatment causal effects by subgroup discovery: An observational case study in antibiotics treatment of acute rhino-sinusitis.
    Qi W; Abu-Hanna A; van Esch TEM; de Beurs D; Liu Y; Flinterman LE; Schut MC
    Artif Intell Med; 2021 Jun; 116():102080. PubMed ID: 34020753
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Computer-aided biomarker discovery for precision medicine: data resources, models and applications.
    Lin Y; Qian F; Shen L; Chen F; Chen J; Shen B
    Brief Bioinform; 2019 May; 20(3):952-975. PubMed ID: 29194464
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regularized logistic regression with network-based pairwise interaction for biomarker identification in breast cancer.
    Wu MY; Zhang XF; Dai DQ; Ou-Yang L; Zhu Y; Yan H
    BMC Bioinformatics; 2016 Feb; 17():108. PubMed ID: 26921029
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Biomarkers for personalized medicine in GI cancers.
    Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
    Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology.
    Landeck L; Kneip C; Reischl J; Asadullah K
    Exp Dermatol; 2016 May; 25(5):333-9. PubMed ID: 27167702
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of Biomarkers on Personalized Medicine.
    Carrigan P; Krahn T
    Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimal two-stage enrichment design correcting for biomarker misclassification.
    Zang Y; Guo B
    Stat Methods Med Res; 2018 Jan; 27(1):35-47. PubMed ID: 26614756
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
    Foster JC; Taylor JM; Kaciroti N; Nan B
    Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of Variable Selection Methods for Time-to-Event Data in High-Dimensional Settings.
    Gilhodes J; Dalenc F; Gal J; Zemmour C; Leconte E; Boher JM; Filleron T
    Comput Math Methods Med; 2020; 2020():6795392. PubMed ID: 32670394
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models.
    Belhechmi S; Bin R; Rotolo F; Michiels S
    BMC Bioinformatics; 2020 Jul; 21(1):277. PubMed ID: 32615919
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic and predictive signatures for treatment decisions.
    Lee UJ; Tzeng S; Chen YC; Chen JJ
    Biomark Med; 2018 Aug; 12(8):849-859. PubMed ID: 30022678
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sparse regression and marginal testing using cluster prototypes.
    Reid S; Tibshirani R
    Biostatistics; 2016 Apr; 17(2):364-76. PubMed ID: 26614384
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identifying predictive markers for personalized treatment selection.
    Shen Y; Cai T
    Biometrics; 2016 Dec; 72(4):1017-1025. PubMed ID: 26999054
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Estimating mean local posterior predictive benefit for biomarker-guided treatment strategies.
    Huang M; Hobbs BP
    Stat Methods Med Res; 2019 Sep; 28(9):2820-2833. PubMed ID: 30037304
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
    Donovan MJ; Cordon-Cardo C
    Mol Diagn Ther; 2017 Apr; 21(2):115-123. PubMed ID: 28000172
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ensemble survival trees for identifying subpopulations in personalized medicine.
    Chen YC; Chen JJ
    Biom J; 2016 Sep; 58(5):1151-63. PubMed ID: 27073016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.